Journal
JOURNAL OF PHARMACY AND PHARMACOLOGY
Volume 63, Issue 7, Pages 893-903Publisher
WILEY
DOI: 10.1111/j.2042-7158.2011.01291.x
Keywords
antimicrobial; dendrimers; hydroxypyridinones; iron; polymers
Categories
Funding
- National Natural Science Foundation of China [20972138]
- Ningbo Science and Technology Bureau, Zhejiang Province [2007C10066]
- Qianjiang Scholars Fund, Zhejiang Province [2010R10051]
Ask authors/readers for more resources
Objectives In recent years, macromolecular iron chelators have received increasing attention as human therapeutic agents. The objectives of this article are: one, to discuss the factors which should be considered when designing iron binding macromolecules as human therapeutic agents, and two, to report recent achievements in the design and synthesis of appropriate macromolecular chelators that have resulted in the production of a number of agents with therapeutic potential. Key findings Macromolecular drugs exhibit unique pharmaceutical properties that are fundamentally different from their traditional small-molecule counterparts. By virtue of their high-molecular-weight characteristics, many are confined to extracellular compartments, for instance, the serum and the gastrointestinal tract. In addition, they have potential for topical administration. Consequently, these macromolecular drugs are free from many of the toxic effects that are associated with their low-molecular-weight analogues. Summary The design and synthesis of macromolecular iron chelators provides a novel aspect to chelation therapy. 3-Hydroxypyridin-4-one hexadentate-based macromolecular chelators have considerable potential for the development of new treatments for iron overload and for topical treatment of infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available